儿童新诊断T细胞急性淋巴细胞白血病与T淋巴母细胞淋巴瘤的治疗策略
本文综述儿童T细胞急性淋巴细胞白血病(T-ALL)和T淋巴母细胞淋巴瘤(T-LBL)的治疗进展,指出尽管未纳入新药,强化T-ALL专属方案(如天冬酰胺酶强化、地塞米松诱导、安全省略颅脑放疗)已显著改善预后。文章通过代表性病例讨论微小残留病(MRD)风险分层、早期T细胞前体ALL等高危亚型治疗,以及不同协作组在奈拉滨使用等治疗差异,并给出当前方案依据。
要点
- 强化T-ALL专属方案(天冬酰胺酶强化、地塞米松诱导、安全省略颅脑放疗)显著改善儿童预后。
- MRD风险分层用于指导治疗强度,高危亚型如早期T细胞前体ALL需特殊处理。
- 不同协作组在奈拉滨使用等治疗上存在差异,需依据当前方案合理选择。
核心结论
- 尽管未纳入新药,强化T-ALL专属方案已显著改善儿童T-ALL预后。
- 通过代表性病例强调天冬酰胺酶强化、地塞米松诱导和安全省略颅脑放疗等关键变化。
主要发现
- 强化T-ALL专属方案(包括天冬酰胺酶强化、地塞米松诱导、安全省略颅脑放疗)带来预后显著改善。
- 近期试验探索了基于MRD的风险分层以及早期T细胞前体ALL等高危亚型的治疗。
- 不同协作组在奈拉滨使用等治疗上存在当前差异。
临床怎么用
- 临床可参考强化T-ALL专属方案,包括天冬酰胺酶强化、地塞米松诱导和安全省略颅脑放疗。
- 应实施基于MRD的风险分层,并针对早期T细胞前体ALL等高危亚型采取相应治疗。
- 需注意不同协作组在奈拉滨使用等治疗上的差异,并依据当前方案依据进行选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive malignancy that has historically been associated with a very poor prognosis. Nevertheless, despite a lack of incorporation of novel agents, the development of intensified T-ALL-focused protocols has resulted in significant improvements in outcome in children. Through the use of several representative cases, we highlight the key changes that have driven these advances including asparaginase intensification, the use of induction dexamethasone, and the safe omission of cranial radiotherapy. We discuss the results of recent trials to explore key topics including the implementation of risk stratification with minimal residual disease measurement and how to treat high-risk subtypes such as early T-cell precursor ALL. In particular, we address current discrepancies in treatment between different cooperative groups, including the use of nelarabine, and provide rationales for current treatment protocols for both T-ALL and T-lymphoblastic lymphoma.
引用
- Teachey DT, O'Connor D. How I treat newly diagnosed T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma in children. Blood. 2020. PMID: 31738819. doi:10.1182/blood.2019001557
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。